SMARCE1 and triple-negative breast carcinoma: To determine whether SMARCE1-mediated anoikis resistance can be extended to other breast cancer cell lines, we examine the effect of SMARCE1 knockdown in HCC38 (Fig. 3c), a triple-negative breast cancer cell line.